Skip to content
Screener

Amneal Pharmaceuticals, Inc. AMRX Unrealized Gain (Loss), Foreign Currency Transaction, before Tax

Unrealized Gain (Loss), Foreign Currency Transaction, before Tax at other companies

Organon logo
OrganonOGN
-$3M-120%

Other financials

Income statement

See full
Revenue$796.2M+9.9%
Gross profit$334.5M+16.9%
Operating income$129.8M+16.5%
Net income$57.7M+157%
EPS (diluted)$0.18+157%

Balance sheet

See full
Cash & equivalents$127.6M+78.4%
Total debt$2.6B+18.0%
Total equity$33.0M+129%
Total assets$3.8B+10.3%

Cash flow

See full
Operating cash flow-$21.2M-125%
CapEx$30.7M+34.5%
Free cash flow-$51.9M-185%

Valuation

See full
Market cap$5.79B+116%
Enterprise value$8.24B+72.2%
P/E36.8×-756×
P/S1.9×+0.9×

Profitability

See full
Gross margin39.3%+1.7pp
Operating margin14.6%+1.4pp
Net margin5%+4.9pp
FCF margin4.1%-5.8pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity77.8×
Current ratio2.2×+0.8×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ForeignCurrencyTransactionGainLossUnrealized.

The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 5:19 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001723128-26-000031
Line itemSix Months Ended June 30, 2026Six Months Ended June 30, 2025
Net income$147,614$60,228
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Depreciation and amortization90,991120,272
Unrealized foreign currency loss (gain)10,495(11,813)
Amortization of debt issuance costs and discount7,95413,686
Reclassification of cash flow hedge5,788(5,876)
Loss on refinancing3,510
Stock-based compensation19,20815,532

Item 1. Financial Statements (Unaudited)

FAQ

What is Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax?
Amneal Pharmaceuticals, Inc. (AMRX) reported unrealized gain (loss), foreign currency transaction, before tax of -$2.28M in Q2 2026.
How has Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax changed year-over-year?
Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax decreased by 127.7% year-over-year, from $8.22M to -$2.28M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax?
Over 2 years (2021 to 2024), Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax has grown at a 541.0% compound annual growth rate (CAGR), from -$175K to -$7.19M.
What does unrealized gain (loss), foreign currency transaction, before tax mean?
This captures the non-cash impact of exchange rate fluctuations on monetary assets and liabilities denominated in foreign currencies. It highlights the company's exposure to international market volatility before tax effects are applied.

Ask your AI about Amneal Pharmaceuticals, Inc.'s unrealized gain (loss), foreign currency transaction, before tax.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude